TherapeuticsMD (NASDAQ:TXMD) Trading Up 1.5% – Time to Buy?

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s share price was up 1.5% during mid-day trading on Thursday . The company traded as high as $2.07 and last traded at $2.00. Approximately 11,780 shares traded hands during trading, a decline of 56% from the average daily volume of 26,659 shares. The stock had previously closed at $1.97.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

TherapeuticsMD Stock Down 0.5%

The firm has a 50 day moving average price of $2.07 and a 200 day moving average price of $2.05. The stock has a market cap of $23.02 million, a P/E ratio of 33.17 and a beta of 0.60.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Tuesday, May 12th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.12) by $6.13. The company had revenue of $0.72 million during the quarter, compared to analyst estimates of $19.77 million. TherapeuticsMD had a net margin of 5.34% and a return on equity of 0.32%.

Institutional Investors Weigh In On TherapeuticsMD

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its position in shares of TherapeuticsMD by 51.5% during the first quarter. Renaissance Technologies LLC now owns 146,200 shares of the company’s stock worth $295,000 after purchasing an additional 49,700 shares in the last quarter. Citadel Advisors LLC grew its holdings in TherapeuticsMD by 125.5% during the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock valued at $36,000 after buying an additional 19,073 shares in the last quarter. Finally, Tejara Capital Ltd grew its holdings in TherapeuticsMD by 1.9% during the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after buying an additional 6,649 shares in the last quarter. 30.74% of the stock is owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.